TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
about
Genomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid LeukemiaTim-3 and Tim-4 as the potential targets for antitumor therapyBlocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune responseUpdate on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunitiesDNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic DisordersTumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling PathwayRational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem CellsAntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cellsClonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.TIM-3 is a potential prognostic marker for patients with solid tumors: A systematic review and meta-analysis.RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expressionSingle-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.Tim-3 and its role in regulating anti-tumor immunity.Human hemato-lymphoid system mice: current use and future potential for medicine.Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cellsIdentification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia.Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors.Tim-3 expression in cervical cancer promotes tumor metastasis.Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell markerIntegrated differential transcriptome maps of Acute Megakaryoblastic Leukemia (AMKL) in children with or without Down Syndrome (DS)Suppression of cancer relapse and metastasis by inhibiting cancer stemnessAnti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.Essential role of PU.1 in maintenance of mixed lineage leukemia-associated leukemic stem cells.Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.Hypoxia-inducible factors in cancer stem cells and inflammation.Targeted therapy against cancer stem cells.Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.Differential expression and biochemical activity of the immune receptor Tim-3 in healthy and malignant human myeloid cells.Understanding and targeting cancer stem cells: therapeutic implications and challenges.Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity.T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.Understanding of leukemic stem cells and their clinical implications.Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1.Clonal evolution of acute leukemia genomes.Acute myelogenous leukemia stem cells: from Bench to Bedside.TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia.Complexity of cancer stem cells.Stem cell maintenance and disease progression in chronic myeloid leukemia.
P2860
Q26796514-AAEC6243-F1BC-49D4-BDA3-1DF618F469D3Q26799502-FBA4C446-7BE7-4379-B1A5-F6CBBFA738F0Q26863081-628FCD4E-8589-49A3-915E-7E31BE4F2CFEQ28071384-31B86981-A390-41C0-8541-4D5EA6267F15Q28073970-70AE6AF3-6268-4021-A8CC-B6E540977F7BQ28116224-82DD3AC0-310A-4514-87F3-B70D011712DEQ28117255-15E9B841-15B7-4572-98AB-E56C524D0583Q28391575-6D5EA73F-FF91-4981-AF7C-4207531D3AEAQ30637447-23232A1F-0774-438C-B26C-9DEB02900316Q33711497-58D6094A-7503-4981-9031-3079955760A0Q33761878-32C57F39-C1AB-45A3-8EC8-C834F2A69A7CQ33816240-8BDFA45B-1A89-400E-AE7E-B2C82BDEC886Q33834587-CB6F8811-AA24-4E18-9A68-AA1E0C01372AQ33909020-373FCA72-166E-47E3-A8F3-B6C7BBC06E88Q33995307-BB298DFE-C210-403D-9D08-BB5A21BEE7F2Q34047867-3683353C-45BB-47EE-89ED-3F5F8805948FQ34232877-147DD465-3B0E-4E2C-9441-E3C4BB3D64EEQ34497781-513FD2A2-A6E6-410C-BD07-57D8140DD3E7Q34555771-4956767D-15BC-4140-894F-01C582BE8C5CQ34720554-4FCC4F13-20CE-44AB-8114-22E799482E83Q35005153-0F64419D-CE9E-49BA-8786-ED9E81AD69FFQ35090120-9E4E2019-A449-422B-9E89-1765800545BDQ35146288-14ACB2DA-5565-42C3-8A09-FA6B891A9CA4Q35217639-1242C978-D64D-468C-B884-C50098C85F33Q35300118-C8BD7BD5-2F62-42D0-BCDA-106513BB478EQ35705992-64B627D9-A164-4478-AFFD-8F7E77076A51Q35802983-C11F6AE8-447F-4394-B55F-0ECF381AC3B0Q36008395-19E6EC15-1C91-4960-A93B-B3206EFE34B2Q36163066-172BE215-7D3A-4ED5-AB81-7F7C9BDDAE35Q36545301-53743958-37D4-44B9-80EC-998604DCA19AQ36907405-24F73C29-1F2E-4D5D-9F97-C6BF5C41058BQ37259702-85D1AB49-0BB8-4558-92B6-1B4CC9AE1DAFQ37272020-ADE41E73-C260-44F5-99F9-B50DC84B58F6Q37616010-AF1910B9-BACA-41F2-BB58-5D1DDEA7478DQ37628931-1580908F-6AC3-4BF5-B735-F9D2DCFE2F93Q37986426-2D8FE89F-5B26-441F-AAD6-E0B11FCD9401Q38020081-ED77164F-FC0D-475C-82D0-B78A80D36109Q38035447-32BBC194-B5E6-4A3E-96B3-D02BF7B659D6Q38062506-2FFB843C-99BE-4766-A86B-BEE0F811C28AQ38095422-A71FF98B-0395-406F-A8A6-1409C8701F32
P2860
TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
@en
TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
@nl
type
label
TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
@en
TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
@nl
prefLabel
TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
@en
TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
@nl
P2093
P1433
P1476
TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
@en
P2093
Hiromi Iwasaki
Katsuto Takenaka
Koichi Akashi
Shin-ichiro Takayanagi
Shingo Urata
Takahiro Shima
Takanori Teshima
Toshihiro Miyamoto
Toshiyuki Tanaka
Yoshikane Kikushige
P304
P356
10.1016/J.STEM.2010.11.014
P407
P577
2010-12-01T00:00:00Z